Maurizio Nicola D'Alterio

Dr. Maurizio Nicola D'Alterio

University of Cagliari
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2016 in Gynecological Endocrinology
Verified
Journal Article
Closed access
APA. Pontis
A. Pontis
Maurizio Nicola D'AlterioMaurizio Nicola D'Alterio
Maurizio Nicola D'Alterio
SPS. Pirarba
S. Pirarba
CAC. de Angelis
C. de Angelis
RTR. Tinelli
R. Tinelli
Stefano AngioniStefano Angioni
Stefano Angioni
Adenomyosis is a heterogeneous gynaecologic condition with a range of clinical presentations, the most common being heavy menstrual bleeding and dysmenorrhoea; however, patients can also be asymptomatic. Several studies support the theory that adenomyosis results from invasion of the endometrium into the myometrium, causing alterations in the junctional zone. These changes are commonly seen on imaging studies, such as transvaginal ultrasound and magnetic resonance imaging. The aim of this review is to discuss the medical approach to the management of adenomyosis symptoms, including pain and abnormal uterine bleeding. The standard treatment of adenomyosis is hysterectomy, but there is no medical therapy to treat the symptoms of adenomyosis while still allowing patients to conceive. Medical therapies using suppressive hormonal treatments, such as continuous use of oral contraceptive pills, high-dose progestins, selective oestrogen receptor modulators, selective progesterone receptor modulators, the levonorgestrel-releasing intrauterine device, aromatase inhibitors, danazol, and gonadotrophin receptor hormone agonists can temporarily induce regression of adenomyosis and improve the symptoms.

9 May 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Salvatore Giovanni VitaleSalvatore Giovanni Vitale
Salvatore Giovanni Vitale
RWRafał Watrowski
Rafał Watrowski
Fabio BarraFabio Barra
Fabio Barra
Maurizio Nicola D'AlterioMaurizio Nicola D'Alterio
Maurizio Nicola D'Alterio
Jose CarugnoJose Carugno
Jose Carugno
Stefano AngioniStefano Angioni
Stefano Angioni
Abnormal uterine bleeding (AUB) is a frequent symptom in perimenopausal women. It is defined as uterine bleeding in which the duration, frequency, or amount of bleeding is considered excessive and negatively affects the woman’s quality of life (QoL) and psychological well-being. In cases of structural uterine pathology, hysterectomy (usually performed via a minimally invasive approach) offers definitive symptom relief and is associated with long-lasting improvement of QoL and sexuality. However, over the past 30 years, uterus-preserving treatments have been introduced as alternatives to hysterectomy. Hysteroscopic polypectomy, myomectomy, or endometrial resection/endometrial ablation are minimally invasive techniques that can be used as an alternative to hysterectomy to treat AUB due to benign conditions. Although associated with high patient satisfaction and short-term improvement in their QoL, hysteroscopic treatments do not eliminate the risk of AUB recurrence or the need for further intervention. Therefore, considering the impact of different treatment options on QoL and sexuality during preoperative shared decision making could help identify the most appropriate and personalized treatment options for perimenopausal women suffering from AUB.

4 August 2021 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
SDSusan Dababou
Susan Dababou
Simone GarzonSimone Garzon
Simone Garzon
Antonio Simone LaganàAntonio Simone Laganà
Antonio Simone Laganà
SFSimone Ferrero
Simone Ferrero
GEGiulio Evangelisti
Giulio Evangelisti
Fabio BarraFabio Barra
Fabio Barra
Uterine myomas and endometriosis are benign hormone-dependent diseases affecting women of reproductive age. Substantial efforts have been made to develop innovative medical options for treating the...

10 November 2020 in Reproductive Sciences
Verified
Journal Article
Open access
PDF file
FMfederica murgia
federica murgia
Stefano AngioniStefano Angioni
Stefano Angioni
Maurizio Nicola D'AlterioMaurizio Nicola D'Alterio
Maurizio Nicola D'Alterio
SPSilvia Pirarba
Silvia Pirarba
ANAntonio Noto
Antonio Noto
FCFrancesca Congiu
Francesca Congiu
Endometriosis is a common disease affecting women in reproductive age. There are several hypotheses on the pathogenesis of this disease. Often, its lesions and symptoms overlap with those of many other medical and surgical conditions, causing a delay in diagnosis. Metabolomics represents a useful diagnostic tool for the study of metabolic changes during a different physiological or pathological status. We used1H-NMR to explore metabolic alteration in a cohort of patients with endometriosis in order to contribute to a better understanding of the pathophysiology of the disease and to suggest new useful biomarkers. Thirty-seven patients were recruited for the metabolomic analysis: 22 patients affected by symptomatic endometriosis and 15 not affected by it. Their serum samples were collected and analyzed with1H-NMR. Multivariate statistical analysis was conducted, followed by univariate and pathway analyses. Partial Least Square Discriminant Analysis (PLS-DA) was performed to determine the presence of any differences between the non-endometriosis and endometriosis samples (R2X = 0.596,R2Y = 0.713,Q2 = 0.635, andp < 0.0001). β-hydroxybutyric acid and glutamine were significantly increased, whereas tryptophan was significantly decreased in the endometriosis patients. ROC curves were built to test the diagnostic power of the metabolites (β-hydroxybutyric acid: AUC = 0.85 CI = 0.71–0.99; glutamine: AUC = 0.83 CI = 0.68–0.98; tryptophan: AUC = 0.75 CI = 0.54–0.95; β-hydroxybutyric acid + glutamine + tryptophan AUC = 0.92 CI = 0.81–1). The metabolomic approach enabled the identification of several metabolic alterations occurring in women with endometriosis. These findings may provide new bases for a better understanding of the pathophysiological mechanisms of the disease and for the discovery of new biomarkers. Trial registration number NCT02337816

25 March 2019 in Gynecological Endocrinology
Verified
Journal Article
Closed access
DDDanilo Deiana
Danilo Deiana
SGStefano Gessa
Stefano Gessa
MAMichela Anardu
Michela Anardu
ADAngelos Daniilidis
Angelos Daniilidis
LNLuigi Nappi
Luigi Nappi
Stefano AngioniStefano Angioni
Stefano Angioni
This review aimed to critically evaluate the review, observational, cohort, and case–control studies performed so far in order to assess the association between endometriosis and genetics. The search strategies used included an online search of the MEDLINE database and a manual search of relevant publications and reviews. Additional reports were collected by systematically reviewing all references from the retrieved papers. Family studies have long suggested that genetic factors play a role in the etiology of endometriosis. Nevertheless, until now, studies on candidate genes have revealed inconsistent and contradictory evidence, leading to more questions rather than clear answers. It is possible that recent technological improvements in genetic evaluation could allow for a better understanding of the pathogenic mechanisms of endometriosis in the near future.

1 March 2019 in Human Reproduction Open
Verified
Journal Article
Open access
FMFrancesco Giuseppe Martire
Francesco Giuseppe Martire
LAL Alio
L Alio
Stefano AngioniStefano Angioni
Stefano Angioni
SAS Arena
S Arena
LBLudovica Bartiromo
Ludovica Bartiromo
Errico ZupiErrico Zupi
Errico Zupi
A network of endometriosis experts from 16 Italian academic departments and teaching hospitals distributed all over the country made a critical appraisal of the available evidence and definition of 10 suggestions regarding measures to be de-implemented. Strong suggestions were made only when high-quality evidence was available. The aim was to select 10 low-value medical interventions, characterized by an unfavorable balance between potential benefits, potential harms, and costs, which should be discouraged in women with endometriosis. The following suggestions were agreed by all experts: do not suggest laparoscopy to detect and treat superficial peritoneal endometriosis in infertile women without pelvic pain symptoms; do not recommend controlled ovarian stimulation and IUI in infertile women with endometriosis at any stage; do not remove small ovarian endometriomas (diameter <4 cm) with the sole objective of improving the likelihood of conception in infertile patients scheduled for IVF; do not remove uncomplicated deep endometriotic lesions in asymptomatic women, and also in symptomatic women not seeking conception when medical treatment is effective and well tolerated; do not systematically request second-level diagnostic investigations in women with known or suspected non-subocclusive colorectal endometriosis or with symptoms responding to medical treatment; do not recommend repeated follow-up serum CA-125 (or other currently available biomarkers) measurements in women successfully using medical treatments for uncomplicated endometriosis in the absence of suspicious ovarian cysts; do not leave women undergoing surgery for ovarian endometriomas and not seeking immediate conception without post-operative long-term treatment with estrogen–progestins or progestins; do not perform laparoscopy in adolescent women (<20 years) with moderate–severe dysmenorrhea and clinically suspected early endometriosis without prior attempting to relieve symptoms with estrogen–progestins or progestins; do not prescribe drugs that cannot be used for prolonged periods of time because of safety or cost issues as first-line medical treatment, unless estrogen–progestins or progestins have been proven ineffective, not tolerated, or contraindicated; do not use robotic-assisted laparoscopic surgery for endometriosis outside research settings.Our proposal is to better address medical and surgical approaches to endometriosis de-implementing low-value interventions, with the aim to prevent unnecessary morbidity, limit psychological distress, and reduce the burden of treatment avoiding medical overuse and allowing a more equitable distribution of healthcare resources.